CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 15 enrolled
Drug / intervention
5-hydroxytryptophan and Creatine monohydratedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02356107
NCT02356107Phase 4Completed

5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females

Perry Renshaw·interventional·Posted Feb 5, 2015·Updated Jan 29, 2018

In Brief

A Phase 4 clinical trial evaluating 5-hydroxytryptophan and Creatine monohydrate for Major Depressive Disorder. Completed, enrolled 15 participants across 1 site.

Detailed Summary

The investigators hypothesize that the administration of two widely available, naturally occurring dietary supplements, 5 hydroxytryptophan and creatine monohydrate, will reduce the severity of depression in individuals exposed to chronic hypoxia by living at altitude. The purpose of this study is to determine if 8 weeks of dietary augmentation with oral 5 g creatine daily and 100 mg 5-HTP twice daily reduces hypoxia-related depressive symptoms measured by the 17-item Hamilton Depression Rating Scale (HAM-D) in women with SSRI or SNRI-resistant depression.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 5, 2015
Enrollment StartApr 1, 2015
Primary CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 11.4 years ago

Interventions

5-hydroxytryptophan and Creatine monohydratedrug